407 related articles for article (PubMed ID: 15749859)
1. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.
McKallip RJ; Nagarkatti M; Nagarkatti PS
J Immunol; 2005 Mar; 174(6):3281-9. PubMed ID: 15749859
[TBL] [Abstract][Full Text] [Related]
2. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.
Springs AE; Karmaus PW; Crawford RB; Kaplan BL; Kaminski NE
J Leukoc Biol; 2008 Dec; 84(6):1574-84. PubMed ID: 18791168
[TBL] [Abstract][Full Text] [Related]
3. The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2.
Newton CA; Lu T; Nazian SJ; Perkins I; Friedman H; Klein TW
J Leukoc Biol; 2004 Oct; 76(4):854-61. PubMed ID: 15258190
[TBL] [Abstract][Full Text] [Related]
4. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection.
Klein TW; Newton CA; Nakachi N; Friedman H
J Immunol; 2000 Jun; 164(12):6461-6. PubMed ID: 10843702
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
6. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
7. Δ9-Tetrahydrocannabinol leads to endoplasmic reticulum stress and mitochondrial dysfunction in human BeWo trophoblasts.
Lojpur T; Easton Z; Raez-Villanueva S; Laviolette S; Holloway AC; Hardy DB
Reprod Toxicol; 2019 Aug; 87():21-31. PubMed ID: 31054322
[TBL] [Abstract][Full Text] [Related]
8. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.
Qamri Z; Preet A; Nasser MW; Bass CE; Leone G; Barsky SH; Ganju RK
Mol Cancer Ther; 2009 Nov; 8(11):3117-29. PubMed ID: 19887554
[TBL] [Abstract][Full Text] [Related]
9. CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection.
Newton CA; Chou PJ; Perkins I; Klein TW
J Neuroimmune Pharmacol; 2009 Mar; 4(1):92-102. PubMed ID: 18792785
[TBL] [Abstract][Full Text] [Related]
10. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo.
McKallip RJ; Lombard C; Martin BR; Nagarkatti M; Nagarkatti PS
J Pharmacol Exp Ther; 2002 Aug; 302(2):451-65. PubMed ID: 12130702
[TBL] [Abstract][Full Text] [Related]
11. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells.
Yuan M; Kiertscher SM; Cheng Q; Zoumalan R; Tashkin DP; Roth MD
J Neuroimmunol; 2002 Dec; 133(1-2):124-31. PubMed ID: 12446015
[TBL] [Abstract][Full Text] [Related]
12. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
Zhu LX; Sharma S; Stolina M; Gardner B; Roth MD; Tashkin DP; Dubinett SM
J Immunol; 2000 Jul; 165(1):373-80. PubMed ID: 10861074
[TBL] [Abstract][Full Text] [Related]
13. Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.
Sido JM; Nagarkatti PS; Nagarkatti M
J Leukoc Biol; 2015 Sep; 98(3):435-47. PubMed ID: 26034207
[TBL] [Abstract][Full Text] [Related]
14. Activation of CB
Joffre J; Yeh CC; Wong E; Thete M; Xu F; Zlatanova I; Lloyd E; Kobzik L; Legrand M; Hellman J
J Immunol; 2020 Jun; 204(12):3339-3350. PubMed ID: 32385136
[No Abstract] [Full Text] [Related]
15. Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.
Lombard C; Hegde VL; Nagarkatti M; Nagarkatti PS
J Pharmacol Exp Ther; 2011 Nov; 339(2):607-17. PubMed ID: 21831965
[TBL] [Abstract][Full Text] [Related]
16. Δ-Tetrahydrocannabinol induces cytotoxicity in macrophage J774-1 cells: involvement of cannabinoid receptor 2 and p38 MAPK.
Yamaori S; Ishii H; Chiba K; Yamamoto I; Watanabe K
Toxicology; 2013 Dec; 314(2-3):254-61. PubMed ID: 24184660
[TBL] [Abstract][Full Text] [Related]
17. Δ9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2.
Karmaus PW; Chen W; Crawford R; Kaplan BL; Kaminski NE
Toxicol Sci; 2013 Feb; 131(2):419-33. PubMed ID: 23152191
[TBL] [Abstract][Full Text] [Related]
18. Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol.
Chen W; Crawford RB; Kaplan BL; Kaminski NE
J Neuroimmune Pharmacol; 2015 Jun; 10(2):344-55. PubMed ID: 25900076
[TBL] [Abstract][Full Text] [Related]
19. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells.
Greenhough A; Patsos HA; Williams AC; Paraskeva C
Int J Cancer; 2007 Nov; 121(10):2172-80. PubMed ID: 17583570
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress and cannabinoid receptor expression in type-2 diabetic rat pancreas following treatment with Δ⁹-THC.
Coskun ZM; Bolkent S
Cell Biochem Funct; 2014 Oct; 32(7):612-9. PubMed ID: 25187240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
